Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
Study Identifier:
ALXN1840-HV-103
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1840
- Drug: Bupropion Hydrochloride
Date
Oct 2020 - May 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 50 Years
Requirements Information
Sex
Female & Male
Age
18 - 50 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1840
- Drug: Bupropion Hydrochloride
Date
Oct 2020 - May 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 50 Years years
Requirements Information
Protocol Summary
This is a Phase 1, randomized, 2-period, 2-sequence, cross-over study designed to determine the effect of ALXN1840 on the metabolism of bupropion, a sensitive cytochrome P450 2B6 (CYP2B6) substrate, in healthy male and female participants. The safety and tolerability of ALXN1840 will be determined along with ALXN1840 pharmacokinetics (PK) in plasma as measured via total molybdenum with the coadministration of bupropion.
Trial Locations
Location
Status
Location
Clinical Trial Site
Austin, Texas, United States, 78744
Status
N/A